Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation
Liver cancer: Common anesthetic can accelerate tumor progression Researchers warn against using the anesthetic dexmedetomidine (DEX) in liver cancer patients after indications that it promotes tumor growth. Concerns have been raised that certain anesthetics, including DEX, can accelerate the progres...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-07-01
|
| Series: | Experimental and Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s12276-020-0461-6 |
| _version_ | 1819156754074697728 |
|---|---|
| author | Peng Chen Xiaojun Luo Guanqi Dai Yuchuan Jiang Yue Luo Shuang Peng Hao Wang Penghui Xie Chen Qu Wenyu Lin Jian Hong Xue Ning Aimin Li |
| author_facet | Peng Chen Xiaojun Luo Guanqi Dai Yuchuan Jiang Yue Luo Shuang Peng Hao Wang Penghui Xie Chen Qu Wenyu Lin Jian Hong Xue Ning Aimin Li |
| author_sort | Peng Chen |
| collection | DOAJ |
| description | Liver cancer: Common anesthetic can accelerate tumor progression Researchers warn against using the anesthetic dexmedetomidine (DEX) in liver cancer patients after indications that it promotes tumor growth. Concerns have been raised that certain anesthetics, including DEX, can accelerate the progression of cancerous tumors, but the precise effects of DEX on liver cancer tumors are unclear. Most liver cancers develop in patients who already have fibrosis, a build-up of scarred tissue in the liver. This tissue accumulation stems from the activation of hepatic stellate cells (HSCs) during liver damage. Using human cancer cell lines and mouse models, Aimin Li and Xue Ning at the Southern Medical University, Guangzhou, China and co-workers demonstrated that DEX interacts with HSCs via a receptor protein on their cell surface, further enhancing activation levels. Activated HSCs in turn secrete factors that accelerate tumor growth and invasion. |
| first_indexed | 2024-12-22T15:57:53Z |
| format | Article |
| id | doaj.art-80f5f3dfe91b425cb22d2f4e052fdd0c |
| institution | Directory Open Access Journal |
| issn | 1226-3613 2092-6413 |
| language | English |
| last_indexed | 2024-12-22T15:57:53Z |
| publishDate | 2020-07-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Experimental and Molecular Medicine |
| spelling | doaj.art-80f5f3dfe91b425cb22d2f4e052fdd0c2022-12-21T18:20:45ZengNature Publishing GroupExperimental and Molecular Medicine1226-36132092-64132020-07-015271062107410.1038/s12276-020-0461-6Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activationPeng Chen0Xiaojun Luo1Guanqi Dai2Yuchuan Jiang3Yue Luo4Shuang Peng5Hao Wang6Penghui Xie7Chen Qu8Wenyu Lin9Jian Hong10Xue Ning11Aimin Li12Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityDepartment of Pathophysiology, School of Medicine, Jinan UniversityLaboratory of Molecular Medicine, School of Traditional Chinese Medicine, Southern Medical UniversityLaboratory of Molecular Medicine, School of Traditional Chinese Medicine, Southern Medical UniversitySchool of Medicine, Jinan UniversityGastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical SchoolCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityCancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical UniversityLiver cancer: Common anesthetic can accelerate tumor progression Researchers warn against using the anesthetic dexmedetomidine (DEX) in liver cancer patients after indications that it promotes tumor growth. Concerns have been raised that certain anesthetics, including DEX, can accelerate the progression of cancerous tumors, but the precise effects of DEX on liver cancer tumors are unclear. Most liver cancers develop in patients who already have fibrosis, a build-up of scarred tissue in the liver. This tissue accumulation stems from the activation of hepatic stellate cells (HSCs) during liver damage. Using human cancer cell lines and mouse models, Aimin Li and Xue Ning at the Southern Medical University, Guangzhou, China and co-workers demonstrated that DEX interacts with HSCs via a receptor protein on their cell surface, further enhancing activation levels. Activated HSCs in turn secrete factors that accelerate tumor growth and invasion.https://doi.org/10.1038/s12276-020-0461-6 |
| spellingShingle | Peng Chen Xiaojun Luo Guanqi Dai Yuchuan Jiang Yue Luo Shuang Peng Hao Wang Penghui Xie Chen Qu Wenyu Lin Jian Hong Xue Ning Aimin Li Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation Experimental and Molecular Medicine |
| title | Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| title_full | Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| title_fullStr | Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| title_full_unstemmed | Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| title_short | Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| title_sort | dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation |
| url | https://doi.org/10.1038/s12276-020-0461-6 |
| work_keys_str_mv | AT pengchen dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT xiaojunluo dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT guanqidai dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT yuchuanjiang dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT yueluo dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT shuangpeng dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT haowang dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT penghuixie dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT chenqu dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT wenyulin dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT jianhong dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT xuening dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation AT aiminli dexmedetomidinepromotestheprogressionofhepatocellularcarcinomathroughhepaticstellatecellactivation |